<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659529</url>
  </required_header>
  <id_info>
    <org_study_id>851R14-8510M3</org_study_id>
    <nct_id>NCT00659529</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease</brief_title>
  <official_title>The Role of Phosphodiesterase Inhibitors in CF Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sildenafil can decrease inflammation in CF
      lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label study that examines the use of sildenafil (Revatio) in clinically
      stable patients with mild to moderate CF lung disease. The length of participation for each
      subject will be approximately 10 weeks, and will consist of a screening visit, a study visit
      for initiation of study drug if subject qualifies, interim visits to escalate drug dose,
      obtain drug levels, review concomitant medications and assess side effects, a visit at the
      end of the therapy period (to reassess inflammatory markers, laboratory studies and side
      effects,) and a follow-up assessment 2 weeks after subject completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum Elastase</measure>
    <time_frame>Pre/post therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Breath Condensate pH</measure>
    <time_frame>Pre/post therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFQ-R</measure>
    <time_frame>Pre/post therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sildenafil Levels</measure>
    <time_frame>Pre/during therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF based on the following criteria:

               -  Positive sweat chloride ≥60mEq/liter (by pilocarpine iontophoresis) and/or

               -  Genotype with two identifiable mutations consistent with CF, and accompanied by
                  one or more clinical features consistent with the CF phenotype

          -  Male or female patients ≥ 12 years of age

          -  FEV1 ≥ 50% predicted (Knudson) 31

          -  Clinically stable without evidence of acute upper or lower respiratory tract infection
             or current pulmonary exacerbation within the 14 days prior to the screening visit

          -  Ability to reproducibly perform spirometry (according to ATS criteria)

          -  Ability to produce at least 1mL of sputum spontaneously, or be willing to undergo
             sputum induction

          -  Ability to understand and sign a written informed consent or assent and comply with
             the requirements of the study

          -  Chronic bacterial colonization (3 documented positive cultures in the prior 2 years of
             which at least one was obtained in the 3 months prior to randomization)

        Exclusion Criteria:

          -  History of hypersensitivity to sildenafil

          -  Use of an investigational agent within the 4-week period prior to Visit 1 (Day 0)

          -  Breastfeeding, pregnant, or verbal expression of unwillingness to practice an
             acceptable birth control method (abstinence, hormonal or barrier methods, partner
             sterilization or intrauterine device) during participation in the study

          -  Daily use of systemic corticosteroids and/or NSAIDs within 4 weeks of the study or as
             needed use within 72 hours prior to the screening visit

          -  History of significant hepatic (SGOT or SGPT &gt; 3 times the upper limit of normal at
             screening, documented biliary cirrhosis, or portal hypertension), cardiovascular
             (history of aortic stenosis, coronary artery disease, pulmonary hypertension with
             right ventricular systolic pressure &gt;55 mmHg or life-threatening arrhythmia),
             neurological (history of stroke), hematologic (history of bleeding diathesis),
             ophthalmologic (history of retinal impairment or non-arteritic ischemic optic
             neuritis) or renal impairment (creatinine &gt;1.8 mg/dL.)

          -  Inability to swallow pills

          -  Previous lung transplantation

          -  Use of concomitant nitrates, α-blocker, or Ca channel blocker

          -  Use of concomitant medications known to be potent inhibitors of CYP3A4 (e.g.
             ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin, rifampin)

          -  Presence of a condition or abnormality that in the opinion of the investigator would
             compromise the safety of the subject or the quality of the data

          -  Weight less than 40 kg

          -  History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years
             of screening

          -  Resting room air oxygen saturation &lt;93%

          -  History of migraines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Taylor-Cousar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Poschet JF, Timmins GS, Taylor-Cousar JL, Ornatowski W, Fazio J, Perkett E, Wilson KR, Yu HD, de Jonge HR, Deretic V. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L712-9. Epub 2007 Jun 22.</citation>
    <PMID>17586695</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <results_first_submitted>April 1, 2014</results_first_submitted>
  <results_first_submitted_qc>April 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2014</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jennifer Brandorff</investigator_full_name>
    <investigator_title>Manager, Clinical Research Services, Regulatory</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>inflammation</keyword>
  <keyword>pH</keyword>
  <keyword>EBC</keyword>
  <keyword>sputum biomarkers</keyword>
  <keyword>phosphodiesterase inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Phosphodiesterase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open-label (All Subjects)</title>
          <description>All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
sildenafil: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36">There were 9 screen failures (subjects who did not meet inclusion/exclusion criteria)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="27">Received at least one dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">4 patients withdrew as a result of side effects. 3 subjects were withdrawn by the investigator.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patiens who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Open-label (All Subjects)</title>
          <description>All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
sildenafil: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1% predicted</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.5" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum Elastase</title>
        <time_frame>Pre/post therapy</time_frame>
        <population>Subjects who completed 6 weeks of sildenafil and had available data for pre/post 6 weeks of sildenafil were analyzed. One subject presented to the final study visit with 1 week of previously unreported symptoms consistent with pulmonary exacerbation, and therefore, efficacy data was not analyzed on that subject as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label (All Subjects)</title>
            <description>All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
sildenafil: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Elastase</title>
          <population>Subjects who completed 6 weeks of sildenafil and had available data for pre/post 6 weeks of sildenafil were analyzed. One subject presented to the final study visit with 1 week of previously unreported symptoms consistent with pulmonary exacerbation, and therefore, efficacy data was not analyzed on that subject as pre-specified in the protocol.</population>
          <units>micrograms/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57" lower_limit="-119" upper_limit="-18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Breath Condensate pH</title>
        <time_frame>Pre/post therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CFQ-R</title>
        <time_frame>Pre/post therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Sildenafil Levels</title>
        <time_frame>Pre/during therapy</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open-label (All Subjects)</title>
          <description>All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
sildenafil: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distal Intestinal Obstruction Syndrome</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CF pulmonary exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat/throat clearing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rhinorhhea/congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Increased cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Increased/thicker sputum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest tigntness/congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer L. Taylor-Cousar, MD</name_or_title>
      <organization>National Jewish Health</organization>
      <phone>(303) 270-2764</phone>
      <email>Taylor-CousarJ@NJHealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

